In the world of diagnostic imaging, physicians often turn to magnetic resonance imaging, or MRI, to diagnose a wide variety of diseases and conditions. For patients suspected of certain conditions, such as inflammatory or infectious diseases, an MRI contrast agent is used to help improve diagnostic accuracy. Unfortunately, the chemical makeup of the most common contrast agents currently on the market — gadolinium-based contrast agents — can have potential long-term toxicity risks in the bodies of individuals with poor kidney function, which affects a population of nearly 2 million patients globally.